Taste masking technologies in oral pharmaceuticals: recent developments and approaches

Drug Development and Industrial Pharmacy
Harmik SohiRoop K Khar

Abstract

Taste is one of the most important parameters governing patient compliance. Undesirable taste is one of several important formulation problems that are encountered with certain drugs. Oral administration of bitter drugs with an acceptable degree of palatability is a key issue for health care providers, especially for pediatric patients. Several oral pharmaceuticals, numerous food and beverage products, and bulking agents have unpleasant, bitter-tasting components. So, any pharmaceutical formulation with a pleasing taste would definitely be preferred over a competitor's product and would translate into better compliance and therapeutic value for the patient and more business and profits for the company. The desire of improved palatability in these products has prompted the development of numerous formulations with improved performance and acceptability. This article reviews the earlier applications and methodologies of taste masking and discusses the most recent developments and approaches of bitterness reduction and inhibition for oral pharmaceuticals.

References

Oct 1, 1992·Journal of Microencapsulation·D R Friend
Jun 1, 1991·Pharmaceutical Research·M Y LuM Vadnere
Jan 1, 1990·Critical Reviews in Food Science and Nutrition·G M Roy
Jul 1, 1990·Journal of Microencapsulation·A Y Ozer, A A Hincal
Sep 1, 1988·Pharmaceutical Research·M A HussainE Shefter
Feb 1, 1993·Biological & Pharmaceutical Bulletin·Y ShiraiY Nakamura
May 20, 1998·Journal of Pharmaceutical Sciences·S TakagiK Toyoshima
Mar 11, 1999·Chemical & Pharmaceutical Bulletin·T YajimaS Itai
Apr 1, 2000·Drug Development and Industrial Pharmacy·M Salazar de Saavedra, I I Saavedra Cuadra
Apr 5, 2000·Pharmaceutica acta Helvetiae·J BarraE Doelker
Jun 29, 2000·Drug Development and Industrial Pharmacy·R AgarwalA Singh
Dec 22, 2000·Chemical Senses·T IshimaruM Furukawa
Jan 5, 2002·Pharmaceutical Development and Technology·J Y ZhengA L Adjei
Jan 29, 2002·Journal of Microencapsulation·M F Al-OmranS I Saleh
Jun 12, 2002·Drug Development and Industrial Pharmacy·Shun Por LiJohn D Higgins
Jun 14, 2002·Journal of Pharmaceutical and Biomedical Analysis·Hang T DuongMadhav S Thakur
Jan 16, 2003·International Journal of Pharmaceutics·Hiroyuki SuzukiYoshiharu Machida
Oct 11, 2003·Biotechnology Advances·B C Saha, K Hayashi
Nov 6, 2003·Chemical & Pharmaceutical Bulletin·Atsu TanigakeTakahiro Uchida
Feb 1, 1951·Journal of the American Pharmaceutical Association·B L LANKFORD, C H BECKER

❮ Previous
Next ❯

Citations

Nov 20, 2008·AAPS PharmSciTech·Divyakumar BoraKiran Bhise
Aug 6, 2010·Biological & Pharmaceutical Bulletin·Yi-Dong YanHan-Gon Choi
May 24, 2012·International Journal of Nanomedicine·Ji-Hee LeeJin-Ho Choy
Dec 24, 2008·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Punit P ShahAtul C Badhan
Mar 18, 2016·Journal of Research in Pharmacy Practice·Fataneh Hashem DabaghianRoshanak Ghods
Jun 22, 2013·Drug Development and Industrial Pharmacy·Du Hyung ChoiSeong Hoon Jeong
Jan 31, 2012·Drug Development and Industrial Pharmacy·Tetsuya ShimoyamaDavid Attwood
May 27, 2015·Drug Development and Industrial Pharmacy·Monica R P Rao, Rohini C Bhingole
Aug 14, 2010·Drug Development and Industrial Pharmacy·Francesco CilurzoLuisa Montanari
Nov 16, 2010·Drug Development and Industrial Pharmacy·Yassin Farag, Claudia S Leopold
Jan 4, 2013·Drug Development and Industrial Pharmacy·Sumita PaulKrutika Sawant
May 9, 2014·Drug Development and Industrial Pharmacy·Paul M YoungDaniela Traini
Feb 11, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Ruut KaartamaPekka Jarho
Nov 26, 2010·International Journal of Pharmaceutics·Katharina WoertzJörg Breitkreutz
Jun 30, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·R P Dixit, S P Puthli
May 22, 2009·International Journal of Pharmaceutics·Hiroaki TasakiKazuhiro Sako
Aug 30, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Andrea MichalkPeter Kleinebudde
Aug 6, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Takayuki YoshidaTakahiro Uchida
Feb 3, 2007·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·P C KayumbaJ P Remon
Mar 2, 2016·Drug Development and Industrial Pharmacy·Baher DaihomHassan Almoazen
Jan 6, 2016·AAPS PharmSciTech·Marten KlukkertClaudia S Leopold
Mar 2, 2016·Drug Development and Industrial Pharmacy·Alaadin AlayoubiHassan Almoazen
Apr 9, 2016·Journal of Pharmaceutical Sciences·Yunmei SongSanjay Garg
Jan 18, 2013·Pharmaceutical Development and Technology·Ulrike StangeHenning Gieseler
Jun 9, 2011·Pharmaceutical Development and Technology·Christine CahyadiPaul Wan Sia Heng

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.